(WELL) Welltower - Ratings and Ratios
Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US95040Q1040
WELL EPS (Earnings per Share)
WELL Revenue
WELL: Senior Housing, Wellness Communities, Outpatient Medical Buildings
Welltower Inc. (NYSE: WELL) is a global leader in healthcare infrastructure, operating a vast portfolio of over 1,500 seniors and wellness housing communities across the United States, United Kingdom, and Canada. By combining elements of housing, healthcare, and hospitality, Welltower creates vibrant communities for mature renters and older adults. The companys real estate portfolio is strategically located in highly attractive micro-markets, boasting exceptional built environments that support the well-being of its residents.
Whats remarkable about Welltower is its unique approach to the real estate business. Rather than viewing itself as a traditional real estate company, Welltower sees itself as a product company wrapped in real estate, driven by strong relationships and an unconventional culture. This approach is supported by a disciplined capital allocation strategy, powered by a data science platform and the Welltower Business System, which drives superior operating results.
From a technical analysis perspective, WELLs stock price is currently at $154.28, above its 20-day and 50-day moving averages, indicating a positive short-term trend. The stock is also above its 200-day moving average, suggesting a longer-term uptrend. The Average True Range (ATR) is 3.14, or 2.03%, indicating moderate volatility.
Using the available
Considering Welltowers strong portfolio and unique business approach, the companys long-term prospects appear promising. However, investors should carefully weigh the potential risks and rewards, taking into account both the technical and fundamental data. A thorough analysis of the companys financials, industry trends, and market conditions will be essential in making an informed investment decision.
Additional Sources for WELL Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle
WELL Stock Overview
Market Cap in USD | 100,074m |
Sector | Real Estate |
Industry | REIT - Healthcare Facilities |
GiC Sub-Industry | Health Care REITs |
IPO / Inception | 2001-01-02 |
WELL Stock Ratings
Growth Rating | 87.3 |
Fundamental | 43.7 |
Dividend Rating | 51.7 |
Rel. Strength | 32.8 |
Analysts | 4.3 of 5 |
Fair Price Momentum | 178.85 USD |
Fair Price DCF | 73.47 USD |
WELL Dividends
Dividend Yield 12m | 1.89% |
Yield on Cost 5y | 6.04% |
Annual Growth 5y | -1.06% |
Payout Consistency | 97.5% |
Payout Ratio | 142.0% |
WELL Growth Ratios
Growth Correlation 3m | 47.4% |
Growth Correlation 12m | 91.3% |
Growth Correlation 5y | 84.8% |
CAGR 5y | 27.78% |
CAGR/Max DD 5y | 0.68 |
Sharpe Ratio 12m | 2.72 |
Alpha | 43.11 |
Beta | 0.414 |
Volatility | 24.23% |
Current Volume | 11336.5k |
Average Volume 20d | 2401k |
As of June 21, 2025, the stock is trading at USD 151.24 with a total of 11,336,479 shares traded.
Over the past week, the price has changed by -0.76%, over one month by +0.01%, over three months by +2.74% and over the past year by +49.72%.
Partly, yes. Based on ValueRay´s Fundamental Analyses, Welltower (NYSE:WELL) is currently (June 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 43.73 and therefor a somewhat positive outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of WELL is around 178.85 USD . This means that WELL is currently undervalued and has a potential upside of +18.26% (Margin of Safety).
Welltower has received a consensus analysts rating of 4.30. Therefor, it is recommend to buy WELL.
- Strong Buy: 10
- Buy: 6
- Hold: 4
- Sell: 0
- Strong Sell: 0
According to our own proprietary Forecast Model, WELL Welltower will be worth about 196 in June 2026. The stock is currently trading at 151.24. This means that the stock has a potential upside of +29.62%.
Issuer | Target | Up/Down from current |
---|---|---|
Wallstreet Target Price | 168 | 11.1% |
Analysts Target Price | 166.4 | 10% |
ValueRay Target Price | 196 | 29.6% |